Aspen ARV tender bid is successfulFollowing the announcement of the Anti-Retroviral (ARV) Tender results by the South African National Treasury Department, Aspen Pharmacare Holdings Limited is pleased to announce that its South African operating company (Aspen) has been successful in winning a number of key products in the tender, including Efavirenz and Tenofovir, in spite of strong competition. The tender is effective for a period of two years, commencing 01 January 2011.
Aspen secured more than 40% of the awarded tender value based upon expected future demand as published in the invitation to tender. The tender value is estimated to be R3.6 billion over 2 years. The South African ARV Tender is the largest of its kind in the world. Aspen has been a leading supplier to this tender since inception of the programme, providing a consistent and reliable supply of high-quality ARV products to the State.
Aspen was awarded a share of the following products:
Product/ % Awarded to Aspen
Abacavir Solution 20mg/ml
40%
Efavirenz Tablets 600mg
70%
Lamivudine Scored Tablets 150mg
70%
Nevirapine Tablets 200mg
40%
Tenofovir Tablets 300g
70%
Zidovudine Tablets 300mg
40%
These tender results are further testament to Aspen’s cost competitiveness against both local and foreign suppliers. Aspen’s range of ARV’s are produced at its world-class manufacturing facilities in Port Elizabeth, South Africa. The Group has invested more than R2 billion over the last five years in extending its manufacturing capability and enhancing the existing facilities. This has resulted in unlocking capacity to accommodate growing demand from Aspen’s domestic and foreign territories and also contributed towards further optimising manufacturing efficiencies.
In his response to the ARV Tender results, Aspen Group Chief Executive, Stephen Saad said: “These tender results confirm Aspen’s cost competitiveness and its credibility as a reliable supplier of pharmaceutical products. Aspen is proud to be able to contribute towards increasing access to affordable, high quality medicines in South Africa and thereby assist in the treatment of the HIV/AIDS pandemic.”
Aspen’s portfolio of ARV’s supports close to 900 000 patients in South Africa daily.
14 December 2010
Sponsor:
Investec Bank Limited
Date: 14/12/2010 11:48:15 Produced by the JSE SENS Department.
The SENS service is an information dissemination service administered by the
JSE Limited (`JSE`). The JSE does not, whether expressly, tacitly or
implicitly, represent, warrant or in any way guarantee the truth, accuracy or
completeness of the information published on SENS. The JSE, their officers,
employees and agents accept no liability for (or in respect of) any direct,
indirect, incidental or consequential loss or damage of any kind or nature,
howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS.
